MA39202B1 - Human antibodies against pd-l1 - Google Patents
Human antibodies against pd-l1Info
- Publication number
- MA39202B1 MA39202B1 MA39202A MA39202A MA39202B1 MA 39202 B1 MA39202 B1 MA 39202B1 MA 39202 A MA39202 A MA 39202A MA 39202 A MA39202 A MA 39202A MA 39202 B1 MA39202 B1 MA 39202B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- antigen
- human antibodies
- binds
- bind
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention fournit des anticorps qui se lient à la protéine de ligand de mort programmée de type 1 (pd-l1) de ligand co-inhibiteur des lymphocytes t, et ses procédés d'utilisation. Selon certains modes de réalisation de l'invention, les anticorps sont des anticorps complètement humains qui se lient à pd-l1. Dans certains modes de réalisation, la présente invention concerne des molécules de liaison aux antigènes multi-spécifiques comprenant une première spécificité de liaison qui se lie à pd-l1 et une seconde spécificité de liaison qui se lie à un antigène de cellule tumorale, un antigène spécifique de cellule infectée, ou un co-inhibiteur des lymphocytes t. Dans certains modes de réalisation, les anticorps selon l'invention sont utiles pour inhiber ou neutraliser l'activité de pd-l1, fournissant ainsi un moyen de traitement d'une maladie ou d'un trouble, notamment un cancer ou une infection virale.The present invention provides antibodies that bind to T-cell co-inhibitory ligand type 1 (pd-11) killed ligand protein, and methods of use thereof. In some embodiments of the invention, the antibodies are fully human antibodies that bind to pd-11. In some embodiments, the present invention relates to multi-specific antigen binding molecules comprising a first binding specificity that binds to pd-11 and a second binding specificity that binds to a tumor cell antigen, an antigen, and specific of infected cell, or a co-inhibitor of the t lymphocytes. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing pd-11 activity, thereby providing a means for treating a disease or disorder, including cancer or viral infection.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461930582P | 2014-01-23 | 2014-01-23 | |
| PCT/US2015/012595 WO2015112805A1 (en) | 2014-01-23 | 2015-01-23 | Human antibodies to pd-l1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA39202B1 true MA39202B1 (en) | 2019-04-30 |
Family
ID=58698441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39202A MA39202B1 (en) | 2014-01-23 | 2015-01-23 | Human antibodies against pd-l1 |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR099147A1 (en) |
| MA (1) | MA39202B1 (en) |
-
2015
- 2015-01-21 AR ARP150100161A patent/AR099147A1/en unknown
- 2015-01-23 MA MA39202A patent/MA39202B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR099147A1 (en) | 2016-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015112805A8 (en) | Human antibodies to pd-l1 | |
| MX2021009852A (en) | Human antibodies to pd-1. | |
| Chitadze et al. | NKG2D-and T-cell receptor-dependent lysis of malignant glioma cell lines by human γδ T cells: Modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors | |
| MA40041B1 (en) | Anti-gitr antibodies and methods of use thereof | |
| ZA202005259B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
| MX2020008445A (en) | Methods for treating cancer with anti-pd-1 antibodies. | |
| MA44560A1 (en) | Anti-cd38 antibodies specific for the treatment of human cancers | |
| MA40913A (en) | ANTIBODY-DRUG CONJUGATES | |
| MA38478A1 (en) | Human anti-pac1 antibodies | |
| MA37761A1 (en) | Proteins for binding to a double receptor antagonist antigen and their uses | |
| AU2018338322A1 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
| MA37407B1 (en) | Antibodies to bradykinin b1 receptor ligands | |
| EA202092420A1 (en) | ANTIBODY AGAINST PD-L1 AND ITS APPLICATION | |
| MA39202B1 (en) | Human antibodies against pd-l1 | |
| Ding et al. | Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression | |
| SE0402536D0 (en) | Immunoregulation in cancer, chronic inflammatory and autoimmune diseases | |
| TR201910330T4 (en) | Medicine containing anti-phospholine d4 antibody. | |
| MA38501B1 (en) | Human antibodies to the respiratory syncytial virus protein f and its methods of use | |
| MA49604A1 (en) | Human antibodies binding to pd-1 | |
| MA40375B1 (en) | Human antibodies against influenza hemagglutinin | |
| WO2021113307A3 (en) | Antibodies against pd-l1 and methods of use thereof | |
| EA202190818A1 (en) | COMBINED THERAPY FOR CANCER | |
| MA37998A1 (en) | Anti-cd3 antibodies, bispecific antigen binding molecules that bind to cd3 and cd20, and their uses | |
| EA201991854A1 (en) | AGONISM ANTIBODIES AGAINST ICOS AND THEIR APPLICATION |